ECSP024365A - Moleculas mutantes solubles ctla4 y sus aplicaciones - Google Patents

Moleculas mutantes solubles ctla4 y sus aplicaciones

Info

Publication number
ECSP024365A
ECSP024365A EC2002004365A ECSP024365A ECSP024365A EC SP024365 A ECSP024365 A EC SP024365A EC 2002004365 A EC2002004365 A EC 2002004365A EC SP024365 A ECSP024365 A EC SP024365A EC SP024365 A ECSP024365 A EC SP024365A
Authority
EC
Ecuador
Prior art keywords
ctla4
mutant molecules
applications
amino acid
molecules
Prior art date
Application number
EC2002004365A
Other languages
English (en)
Inventor
Juergen Bajorath
Robert J Peach
Joseph R Naemura
Peter S Linsley
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ECSP024365A publication Critical patent/ECSP024365A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención ofrece las moléculas mutantes CTLA4 solubles que se ligan con mayor intensidad a los antígenos CD80 y/o CD86 que a los CTLA4 de tipo agresivo o CTLA4 Ig no mutados. Las moléculas CTLA4 solubles tienen una primera secuencia de aminoácido conteniendo el dominio extracelular de CTLA4, donde ciertos residuos de aminoácidos son mutados en las regiones 825- R33 Y M97-G107. Las molécular mutantes de la invención pueden también incluir una segunda secuencia de aminoácidos que aumentan la solubilidad de las moléculas mutantes.
EC2002004365A 2000-05-26 2002-11-26 Moleculas mutantes solubles ctla4 y sus aplicaciones ECSP024365A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26

Publications (1)

Publication Number Publication Date
ECSP024365A true ECSP024365A (es) 2003-03-31

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2002004365A ECSP024365A (es) 2000-05-26 2002-11-26 Moleculas mutantes solubles ctla4 y sus aplicaciones

Country Status (41)

Country Link
EP (3) EP1248802B9 (es)
JP (1) JP4328525B2 (es)
KR (2) KR100889887B1 (es)
CN (2) CN101255192A (es)
AR (1) AR031699A1 (es)
AT (1) ATE271066T1 (es)
AU (2) AU6346601A (es)
BE (1) BE2011C041I2 (es)
BR (1) BRPI0111191B8 (es)
CA (1) CA2409748C (es)
CY (2) CY2011019I1 (es)
CZ (1) CZ304451B6 (es)
DE (2) DE60104282T2 (es)
DK (1) DK1248802T3 (es)
EC (1) ECSP024365A (es)
EE (2) EE05557B1 (es)
EG (1) EG24459A (es)
ES (2) ES2225549T3 (es)
FR (1) FR11C0053I2 (es)
GE (1) GEP20053658B (es)
HK (1) HK1048126B (es)
HU (2) HU228137B1 (es)
IL (1) IL152315A (es)
LT (1) LT5133B (es)
LU (1) LU91902I2 (es)
LV (1) LV12994B (es)
MX (1) MXPA02011534A (es)
MY (1) MY136113A (es)
NO (2) NO330797B1 (es)
PE (1) PE20011338A1 (es)
PL (1) PL206267B1 (es)
PT (1) PT1248802E (es)
RU (1) RU2283847C2 (es)
SI (1) SI1248802T1 (es)
SK (1) SK288131B6 (es)
TR (1) TR200402703T4 (es)
TW (2) TWI319405B (es)
UA (1) UA87432C2 (es)
UY (1) UY26723A1 (es)
WO (1) WO2001092337A2 (es)
ZA (1) ZA200208944B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
SI1935427T1 (en) * 2000-07-03 2018-05-31 Bristol-Myers Squibb Company USE OF HEATED CTLA4 MUTANT MOLECULES
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
PL204899B1 (pl) 2001-05-23 2010-02-26 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
AU2003243152A1 (en) * 2002-04-19 2003-11-03 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
AU2003300276B2 (en) * 2002-12-23 2010-07-01 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US7332303B2 (en) 2002-12-23 2008-02-19 Bristol-Myers Squibb Company Product quality enhancement in mammalian cell culture processes for protein production
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
CA2543484C (en) 2003-10-27 2014-02-04 Amgen Inc. Modulation of immune response to an immunogen with ctla-4 and tnfbp
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
PL2253644T3 (pl) * 2005-12-20 2014-04-30 Bristol Myers Squibb Co Kompozycje i sposoby wytwarzania kompozycji
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
CA2673725C (en) 2006-12-20 2016-01-12 Mmr Information Systems, Inc. Antibodies and methods for making and using them
PT2222697E (pt) 2007-11-01 2013-02-15 Perseid Therapeutics Llc Polipeptídeos imunossupressores e ácidos nucleicos
EP3281955A1 (en) 2008-10-02 2018-02-14 Aptevo Research and Development LLC Cd86 antagonist multi-target binding proteins
US9540426B2 (en) * 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP2545073B1 (en) 2010-03-12 2015-09-30 AbbVie Biotherapeutics Inc. Ctla4 proteins and their uses
JP2014506482A (ja) 2011-02-23 2014-03-17 アムジエン・インコーポレーテツド Ｕｖｃ露光のための細胞培養培地およびそれに関連した方法
WO2013010537A1 (en) 2011-07-20 2013-01-24 Aarhus Universitet Method of treating morphea
WO2013148049A1 (en) * 2012-03-29 2013-10-03 The General Hospital Corporation Recombinant cytotoxic t-lymphocyte-associated protein 4 (ctla4)
ES2777778T3 (es) * 2012-05-11 2020-08-06 Medimmune Ltd Variantes de CTLA-4
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
EP2866823A4 (en) * 2012-06-27 2016-03-02 Orban Biotech Llc CTLA4 FUSION PROTEINS FOR THE TREATMENT OF DIABETES
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
MX376230B (es) 2014-01-13 2025-03-07 Amgen Inc Regulación del metábolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteínas recombinantes.
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
SG10202113019XA (en) 2014-06-04 2021-12-30 Amgen Inc Methods for harvesting mammalian cell cultures
PL3227454T3 (pl) 2014-12-01 2020-07-27 Amgen Inc. Sposób manipulowania poziomem zawartości glikanów w glikoproteinie
US10590457B2 (en) 2015-02-11 2020-03-17 Bristol Myers-Squibb Company Compositions for cell culture and methods of using the same
RS61943B1 (sr) 2015-04-17 2021-07-30 Alpine Immune Sciences Inc Imunomodulatorni proteini sa prilagodljivim afinitetima
EP3347486A4 (en) 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
WO2017083224A1 (en) 2015-11-09 2017-05-18 Bristol-Myers Squibb Company Methods to manipulate quality attributes of polypeptides produced in cho cells
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
EP3515489B1 (en) 2016-09-19 2025-11-05 OncoC4, Inc. Cd80 and cd86 binding protein compositions and uses thereof
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
EP3612023A4 (en) 2017-04-20 2021-05-12 Egenesis, Inc. METHOD FOR PRODUCING GENETICALLY MODIFIED ANIMALS
WO2019074983A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
WO2019136179A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CN115227824A (zh) * 2018-11-12 2022-10-25 中南大学湘雅二医院 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用
JP7713886B2 (ja) 2018-11-30 2025-07-28 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８６バリアント免疫調節タンパク質およびその使用
EP4021479A2 (en) 2019-08-27 2022-07-06 Tonix Pharma Limited Modified tff2 polypeptides
KR20240007293A (ko) 2019-12-06 2024-01-16 리제너론 파아마슈티컬스, 인크. 항-vegf 단백질 조성물 및 이를 생산하는 방법
WO2021226551A1 (en) 2020-05-08 2021-11-11 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins and methods of use thereof
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
KR20230026434A (ko) 2020-06-18 2023-02-24 리제너론 파아마슈티컬스, 인크. 미처리된 c-말단 리신을 정확하게 측정하기 위한 중질 펩티드 접근법
WO2022027013A1 (en) 2020-07-28 2022-02-03 Seagen Inc. Methods and systems for producing polypeptides
WO2023115027A2 (en) 2021-12-16 2023-06-22 Bristol-Myers Squibb Company Detergent for viral inactivation
JP2025507790A (ja) 2022-03-02 2025-03-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高力価抗体のための製造プロセス

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
EP0606217B2 (en) 1991-06-27 2008-12-03 Bristol-Myers Squibb Company Ctl4a receptor, fusion proteins containing it and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
CA2346496A1 (en) * 1998-10-07 2000-04-13 Millennium Pharmaceuticals, Inc. Novel th2-specific molecules and uses thereof
SI1935427T1 (en) * 2000-07-03 2018-05-31 Bristol-Myers Squibb Company USE OF HEATED CTLA4 MUTANT MOLECULES

Also Published As

Publication number Publication date
MXPA02011534A (es) 2004-08-12
NO2011027I2 (es) 2011-12-15
EE201100050A (et) 2011-10-17
BE2011C041I2 (es) 2020-08-20
CA2409748A1 (en) 2001-12-06
FR11C0053I1 (es) 2012-01-13
AU2001263466C1 (en) 2006-10-26
LT5133B (lt) 2004-05-25
IL152315A (en) 2010-04-15
PE20011338A1 (es) 2002-01-13
EP3029062A1 (en) 2016-06-08
CY2011019I2 (el) 2016-12-14
EP1248802A2 (en) 2002-10-16
KR20030009502A (ko) 2003-01-29
PL206267B1 (pl) 2010-07-30
HUP0302201A2 (hu) 2003-10-28
ES2225549T3 (es) 2005-03-16
EE200200659A (et) 2004-06-15
MY136113A (en) 2008-08-29
ZA200208944B (en) 2004-02-13
RU2283847C2 (ru) 2006-09-20
NO2011027I1 (no) 2012-01-09
HK1048126B (en) 2005-03-04
JP2004511213A (ja) 2004-04-15
CN1441810A (zh) 2003-09-10
NO20025656D0 (no) 2002-11-25
TWI314933B (en) 2009-09-21
HK1048126A1 (en) 2003-03-21
EP1248802B9 (en) 2005-05-11
ATE271066T1 (de) 2004-07-15
KR100889887B1 (ko) 2009-03-24
EG24459A (en) 2009-07-16
SK288131B6 (sk) 2013-10-02
UA87432C2 (uk) 2009-07-27
TR200402703T4 (tr) 2004-11-22
CY1117625T1 (el) 2017-04-26
BRPI0111191B8 (pt) 2021-05-25
WO2001092337A2 (en) 2001-12-06
HU228137B1 (en) 2012-12-28
TWI319405B (en) 2010-01-11
TW200906857A (en) 2009-02-16
PL366231A1 (en) 2005-01-24
LV12994B (en) 2003-08-20
SI1248802T1 (en) 2005-02-28
DK1248802T3 (da) 2004-11-15
HUS1300012I1 (hu) 2016-08-29
UY26723A1 (es) 2001-12-28
WO2001092337A3 (en) 2002-05-10
EP1248802B1 (en) 2004-07-14
NO330797B1 (no) 2011-07-18
DE122011100063I1 (de) 2012-06-14
LT2002114A (en) 2003-12-29
CN101255192A (zh) 2008-09-03
JP4328525B2 (ja) 2009-09-09
BRPI0111191B1 (pt) 2019-12-31
EE05557B1 (et) 2012-08-15
CZ304451B6 (cs) 2014-05-14
CA2409748C (en) 2008-09-16
DE60104282D1 (de) 2004-08-19
HK1071931A1 (en) 2005-08-05
FR11C0053I2 (fr) 2013-01-11
AU6346601A (en) 2001-12-11
EE05458B1 (et) 2011-08-15
SK15702002A3 (sk) 2004-01-08
CZ20023892A3 (cs) 2003-09-17
EP1536234A3 (en) 2009-06-03
CN1309735C (zh) 2007-04-11
ES2571852T3 (es) 2016-05-27
EP1536234A2 (en) 2005-06-01
AU2001263466B2 (en) 2006-04-27
IL152315A0 (en) 2003-05-29
PT1248802E (pt) 2004-11-30
GEP20053658B (en) 2005-11-10
EP1536234B1 (en) 2016-03-16
NO20025656L (no) 2002-11-25
DE60104282T2 (de) 2005-10-13
HUP0302201A3 (en) 2010-01-28
AR031699A1 (es) 2003-10-01
CY2011019I1 (el) 2016-12-14
KR100895134B1 (ko) 2009-05-04
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
BR0111191A (pt) 2004-07-06

Similar Documents

Publication Publication Date Title
UY26723A1 (es) Moléculas mutantes de ctla4 solubles y usos de las mismas
CY1106532T1 (el) Ετερολογος εκφραση των πρωτεϊνων της neisseria
ATE376026T1 (de) Klebstoffzusammensetzungen mit selbstorganisierenden molekülen, klebstoffe, gegenstände und verfahren
CY1114626T1 (el) Μεθοδοι κυκλοπολυαιθυλενογλυκολιωσης και πρωτεϊνες/πεπτιδια που παραγονται με αυτες τις μεθοδους
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
DE60236861D1 (de) Kombinatorische bibliotheken von monomerdomänen
CY1109068T1 (el) Υποκατεστημενες πυριδινυλαμινες
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
CY1105194T1 (el) Φωσφονικα παραγωγα γλυκοπεπτιδιων
CY1114584T1 (el) Ανασυνδυασμενα εμβολια και χρηση αυτων
BR0112969A (pt) Método de utilização de dicetopiperazinas e composições contendo-as
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
CY1105758T1 (el) Τροποποιημενη απιμιναση αργινινης
GT200300295A (es) Formas de dosificacion que comprenden un inhibidor de la ptec y un inhibidor de la hmg-coa-reductasa
DE60331224D1 (de) Subtilisin-carlsberg-proteine mit verminderter immunogenität
NO20031860L (no) Kahalalid F
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
DE602004028448D1 (de) Orale zubereitungen enthaltend cladribin
CY1110718T1 (el) Ανοσογονες λιποσωμικες συνθεσεις
ATE315380T1 (de) Epothilon zusammensetzungen
DK1765337T3 (da) Kombination af tenofovir, ritonavir og TMC114
AU2003288229A1 (en) Mixture of at least two fusion proteins, the production thereof and the use of the same
ATE505538T1 (de) Dna-vektoren
BR0116614A (pt) Composições de polìmero biodegradáveis de resposta à água e método de fabricação das mesmas
FI20000219A7 (fi) Antistaattinen biohajoava muovikalvo ja menetelmä sen valmistamiseksi